Rani Therapeutics Holdings, Inc. SEC filings RANI
Rani Therapeutics Holdings, Inc. has 380 filings in SEC EDGAR's recent list, going back to Apr 27, 2021. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 13, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 16, 2026 | — |
| DEF 14A | Proxy statement | Apr 16, 2026 | May 28, 2026 |
| DEF 14C | Information statement | Dec 5, 2025 | Dec 5, 2025 |
| PRE 14C | Filing | Nov 25, 2025 | Nov 25, 2025 |
| DEF 14C | Information statement | Jul 10, 2025 | Jul 10, 2025 |
| PRE 14C | Filing | Jun 30, 2025 | Jun 30, 2025 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEFA14A | Additional proxy material | Apr 16, 2025 | — |
| DEF 14A | Proxy statement | Apr 16, 2025 | May 28, 2025 |
| DEFA14A | Additional proxy material | Apr 17, 2024 | — |
| DEF 14A | Proxy statement | Apr 17, 2024 | May 29, 2024 |
| DEFA14A | Additional proxy material | Apr 11, 2023 | — |
| DEF 14A | Proxy statement | Apr 11, 2023 | May 25, 2023 |
| DEFA14A | Additional proxy material | Apr 13, 2022 | — |
| DEF 14A | Proxy statement | Apr 13, 2022 | May 25, 2022 |
Showing 15 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RANI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- San Jose, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1856725
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.